Clinical Trials Logo

Loss of Heterozygosity clinical trials

View clinical trials related to Loss of Heterozygosity.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03845296 Active, not recruiting - Clinical trials for Stage IV Lung Cancer AJCC v8

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Start date: April 16, 2019
Phase: Phase 2
Study type: Interventional

This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.